查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1236902

肺動脈高壓 (PAH) 治療市場：全球行業趨勢、份額、規模、增長機會、2023-2028 年預測

Pulmonary Arterial Hypertension (PAH) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

2022年全球肺動脈高壓（PAH）藥物市場規模將達到73億美元。展望未來，IMARC集團將在2023年至2028年實現5.2%的增長率（CAGR），預計到2028年到 2020 年達到 99 億美元。

肺動脈高壓 (PAH) 是一種危及生命的疾病，其特徵是連接心臟和肺部的動脈出現高血壓。 肺動脈高壓 (PAH) 是由連接心肺的動脈中的高血壓引起的，導致動脈壁收緊和變窄，對心臟泵血施加更大壓力並削弱肌肉。 在最壞的情況下，心臟泵血的能力會受到損害，最終導致心力衰竭。 PAH 的特徵是呼吸急促、疲勞以及腳踝和腿部腫脹。 它可通過多種測試進行診斷，包括超聲心動圖、計算機斷層掃描 (CT)、胸部 X 光檢查和通氣-灌注研究。 它通常用多種藥物治療，包括內皮素受體拮抗劑 (ERA)、血管擴張劑、鈣通道阻滯劑 (CCB)、抗凝劑、利尿劑和糖甘。 這些藥物可以吸入、注射或口服。

心血管和肺部疾病患病率的增加是推動市場增長的關鍵因素之一。 此外，易患此類疾病的老年人口增加也推動了市場的增長。 此外，過度飲酒、缺乏運動和不健康的飲食習慣等生活方式的改變也會增加患高血壓和高脂血症的風險。 除此之外，用於治療 PAH 的新型孤兒藥和技術先進的設備的開發正在推動市場的增長。 此外，公眾對 PAH 治療的認識提高以及全球醫療基礎設施的改善等因素預計將進一步推動市場。

主要市場細分

  • IMARC Group 對全球肺動脈高壓 (PAH) 治療市場報告的每個子部分的主要趨勢進行了分析，並預測了 2023 年至 2028 年在全球、區域和國家層面的表現。 該報告根據藥物類別、給藥途徑和最終用戶對市場進行分類。

本報告中回答的關鍵問題

  • 全球肺動脈高壓 (PAH) 藥物市場迄今為止進展如何，未來幾年將如何發展？
  • COVID-19 對全球肺動脈高壓 (PAH) 藥物市場有何影響？
  • 主要的區域市場是什麼？
  • 按藥物類別劃分的市場細分情況如何？
  • 基於給藥途徑的市場細分是什麼？
  • 最終用戶的市場細分情況如何？
  • 行業價值鏈中有哪些不同階段？
  • 該行業的主要驅動因素和挑戰是什麼？
  • 全球肺動脈高壓 (PAH) 藥物市場結構和主要參與者是什麼？
  • 您所在行業的競爭力如何？

內容

第一章前言

第 2 章範圍和方法論

  • 調查目的
  • 利益相關者
  • 數據源
    • 主要信息
    • 次要信息
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第 3 章執行摘要

第四章介紹

  • 概覽
  • 主要行業趨勢

第 5 章肺動脈高壓 (PAH) 藥物的全球市場

  • 市場概覽
  • 市場結果
  • COVID-19 的影響
  • 市場預測

第 6 章藥物類別的市場細分

  • 內皮素受體拮抗劑 (ERA)
    • 市場趨勢
    • 市場預測
  • 血管擴張劑
    • 市場趨勢
    • 市場預測
  • 磷酸二酯□ 5 (PDE-5) 抑製劑
    • 市場趨勢
    • 市場預測
  • 可溶性鳥甘酸環化□ (sGC) 興奮劑
    • 市場趨勢
    • 市場預測
  • 鈣通道阻滯劑 (CCB)
    • 市場趨勢
    • 市場預測
  • 前列環素和前列環素類似物
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 7 章按管理劃分的市場細分

  • 吸入
    • 市場趨勢
    • 市場預測
  • 注入
    • 市場趨勢
    • 市場預測
  • 口服給藥
    • 市場趨勢
    • 市場預測

第 8 章最終用戶市場細分

  • 醫院
    • 市場趨勢
    • 市場預測
  • 診所
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 9 章按區域劃分的市場細分

  • 北美
    • 美國
      • 市場趨勢
      • 市場預測
    • 加拿大
      • 市場趨勢
      • 市場預測
  • 亞太地區
    • 中國
      • 市場趨勢
      • 市場預測
    • 日本
      • 市場趨勢
      • 市場預測
    • 印度
      • 市場趨勢
      • 市場預測
    • 韓國
      • 市場趨勢
      • 市場預測
    • 澳大利亞
      • 市場趨勢
      • 市場預測
    • 印度尼西亞
      • 市場趨勢
      • 市場預測
    • 其他
      • 市場趨勢
      • 市場預測
  • 歐洲
    • 德國
      • 市場趨勢
      • 市場預測
    • 法國
      • 市場趨勢
      • 市場預測
    • 英國
      • 市場趨勢
      • 市場預測
    • 意大利
      • 市場趨勢
      • 市場預測
    • 西班牙
      • 市場趨勢
      • 市場預測
    • 俄羅斯
      • 市場趨勢
      • 市場預測
    • 其他
      • 市場趨勢
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場趨勢
      • 市場預測
    • 墨西哥
      • 市場趨勢
      • 市場預測
    • 其他
      • 市場趨勢
      • 市場預測
  • 中東和非洲
    • 市場趨勢
    • 按國家/地區劃分的市場細分
    • 市場預測

第 10 章 SWOT 分析

  • 概覽
  • 力量
  • 弱點
  • 機會
  • 威脅

第11章價值鏈分析

第12章搬運工五力分析

  • 概覽
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章競爭格局

  • 市場結構
  • 主要公司
  • 主要公司簡介
    • Actelion Pharmaceuticals Ltd（Johnson & Johnson）
    • Arena Pharmaceuticals Inc.
    • AstraZeneca PLC
    • Bayer Aktiengesellschaft
    • Daiichi Sankyo Company Limited
    • Gilead Science Inc.
    • GlaxoSmithKline PLC
    • Merck KGaA
    • Novartis International AG
    • Pfizer Inc.
    • United Therapeutics Corporation
Product Code: SR1523A167_Report

The global pulmonary arterial hypertension (PAH) drugs market size reached US$ 7.3 Billion in 2022 Looking forward, IMARC Group expects the market to reach US$ 9.9 Billion by 2028, exhibiting a growth rate (CAGR) of 5.2% during 2023-2028.

Pulmonary arterial hypertension (PAH) refers to a life-threatening medical condition characterized by high blood pressure in the arteries that connect the heart to the lungs. It causes the artery walls to tighten and narrow down, thereby exerting additional pressure on the heart to pump blood and weakening the muscles. In adverse cases, it can also compromise the heart's capacity to pump blood, thus eventually causing heart failure. PAH is characterized by shortness of breath, fatigue and swelling in ankles and legs. It is diagnosed through various tests, such as an echocardiogram, computer tomography (CT) scans, chest X-rays and ventilation-perfusion scans. It is usually treated using various drugs, such as endothelin receptor antagonists (ERAs), vasodilators, calcium channel blockers (CCBs), anticoagulants, diuretics and cardiac glycosides. These drugs can be inhaled, injected or orally administered.

The increasing prevalence of cardiovascular and pulmonary disorders is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population that is more susceptible to such medical ailments is providing a boost to the market growth. In line with this, changes in lifestyles, such as excessive alcohol consumption, a lack of physical activity, and unhealthy dietary patterns, have enhanced the risks of hypertension and high blood pressure. This, along with the development of novel orphan drugs and technologically advanced devices for the treatment of PAH, is favoring the market growth. Other factors, including increasing awareness among the masses regarding the available treatment alternatives for PAH, and improving healthcare infrastructure across the globe, are expected to drive the market further.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global pulmonary arterial hypertension (PAH) drugs market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug class, route of administration and end user.

Breakup by Drug Class:

  • Endothelin Receptor Antagonists (ERAs)
  • Vasodilators
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Soluble Guanylate Cyclase (sGC) Stimulators
  • Calcium Channel Blockers (CCBs)
  • Prostacyclin and Prostacyclin Analogs
  • Others

Breakup by Route of Administration:

  • Inhalation
  • Injectable
  • Oral Administration

Breakup by End User:

  • Hospitals
  • Clinics
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The report has also analysed the competitive landscape of the market with some of the key players being Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation.

Key Questions Answered in This Report:

  • How has the global pulmonary arterial hypertension (PAH) drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global pulmonary arterial hypertension (PAH) drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global pulmonary arterial hypertension (PAH) drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Endothelin Receptor Antagonists (ERAs)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Vasodilators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Phosphodiesterase-5 (PDE-5) Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Soluble Guanylate Cyclase (sGC) Stimulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Calcium Channel Blockers (CCBs)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Prostacyclin and Prostacyclin Analogs
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Inhalation
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectable
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Oral Administration
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Actelion Pharmaceuticals Ltd (Johnson & Johnson)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Arena Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 AstraZeneca PLC
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bayer Aktiengesellschaft
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Daiichi Sankyo Company Limited
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Gilead Science Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 GlaxoSmithKline PLC
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Merck KGaA
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Novartis International AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 United Therapeutics Corporation
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pulmonary Arterial Hypertension Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Drug Class (in %), 2022
  • Figure 4: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Route of Administration (in %), 2022
  • Figure 5: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by End User (in %), 2022
  • Figure 6: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Region (in %), 2022
  • Figure 7: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 8: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase- sGC Stimulators) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase- sGC Stimulators) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and Prostacyclin Analogs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and Prostacyclin Analogs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: North America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: North America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: United States: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: United States: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Canada: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Canada: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: China: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: China: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Japan: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Japan: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: India: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: India: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: South Korea: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: South Korea: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Australia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Australia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Indonesia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Indonesia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Europe: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Europe: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Germany: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Germany: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: France: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: France: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: United Kingdom: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: United Kingdom: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Italy: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Italy: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Spain: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Spain: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Russia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Russia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Latin America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Latin America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Brazil: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Brazil: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Mexico: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Mexico: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 80: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 81: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 82: Global: Pulmonary Arterial Hypertension Drugs Industry: SWOT Analysis
  • Figure 83: Global: Pulmonary Arterial Hypertension Drugs Industry: Value Chain Analysis
  • Figure 84: Global: Pulmonary Arterial Hypertension Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pulmonary Arterial Hypertension Drugs Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
  • Table 3: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 4: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 5: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Pulmonary Arterial Hypertension Drugs Market Structure
  • Table 7: Global: Pulmonary Arterial Hypertension Drugs Market: Key Players